Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Tarceva (erlotinib), gemcitabine and oxaliplatin in untreated locally advanced or metastatic pancreatic cancer
KCT0000137Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Jun 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, gemcitabine, oxaliplatin in pancreatic cancer (PC), sponsored by Boryung. Started Jun 2011; status: recruiting.
02
Drugs
erlotinibgemcitabineoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0000137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000137.